Compare REAL & VYGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | REAL | VYGR |
|---|---|---|
| Founded | 2011 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 227.2M |
| IPO Year | 2019 | 2015 |
| Metric | REAL | VYGR |
|---|---|---|
| Price | $9.70 | $3.79 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 2 |
| Target Price | ★ $17.00 | $16.50 |
| AVG Volume (30 Days) | ★ 4.1M | 556.9K |
| Earning Date | 05-07-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 43.55 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $692,845,000.00 | $10,135,000.00 |
| Revenue This Year | $14.30 | $34.04 |
| Revenue Next Year | $10.15 | $7.92 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 15.38 | N/A |
| 52 Week Low | $4.71 | $2.83 |
| 52 Week High | $17.39 | $5.55 |
| Indicator | REAL | VYGR |
|---|---|---|
| Relative Strength Index (RSI) | 44.65 | 47.25 |
| Support Level | $9.61 | $3.71 |
| Resistance Level | $11.17 | $4.39 |
| Average True Range (ATR) | 0.54 | 0.23 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 77.51 | 39.55 |
The RealReal Inc is an online marketplace for authenticated, resale luxury goods, providing an end-to-end service that unlocks supply and creates a trusted, curated marketplace for buyers globally. Since its inception, the company has cultivated a loyal and engaged consignor and buyer base through continuous investment in its technology platform, logistics infrastructure, brand and people. It offers a wide selection of authenticated, mainly pre-owned luxury goods bearing the brands of thousands of luxury and premium designers, including Cartier, Chanel, Christian Dior, Gucci, Hermes, Louis Vuitton and Rolex. The company offers products across women's fashion, men's fashion, jewelry, and watches, promoting the recirculation of luxury goods and contributing to a more sustainable world.
Voyager Therapeutics Inc is a biotechnology company to leverage the power of human genetics to modify the course of and ultimately cure neurological diseases. Its pipeline includes programs for Alzheimer's disease, or AD; Friedreich's ataxia, or FA; Parkinson's disease, or PD; and multiple other diseases of the central nervous system, or CNS. Many of its programs are derived from its TRACER (Tropism Redirection of AAV by Cell-type-specific Expression of RNA) adeno-associated virus, or AAV, capsid discovery platform, which the company has used to generate novel capsids, or TRACER Capsids, and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous, or IV, dosing. Its segment is developing and commercializing genetic medicine.